Journals / Namık Kemal Tıp Dergisi / 2020 / Cilt: 8 - Sayı: 2

The Prevelance of Irritable Bowel Syndrome in Patients with Ankylosing Spondylitis

ANKİLOZAN SPONDİLİT HASTALARINDA İRRİTABL BARSAK SENDROMU SIKLIĞI

Pages
117–123
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, in patients with AS, especially with high disease activity, gastroenterological complaints should be questioned; and IBS as frequent comorbidity, shouldn’t be ignored in the follow-up

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Irritable bowel syndrome (IBS) is a functional bowel disease, characterized by altered bowel habits and chronic abdominal pain.
📊
Key Findings & Data:IBS has an increased association with inflammatory pathologies such as rheumatoid arthritis (RA), but the role of inflammation in the pathophysiology of IBS hasn’t been clarified yet.
💡
Conclusion & Impact:As a result, in patients with AS, especially with high disease activity, gastroenterological complaints should be questioned; and IBS as frequent comorbidity, shouldn’t be ignored in the follow-up
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Irritable bowel syndrome (IBS) is a functional bowel disease, characterized by altered bowel habits and chronic abdominal pain. IBS has an increased association with inflammatory pathologies such as rheumatoid arthritis (RA), but the role of inflammation in the pathophysiology of IBS hasn’t been clarified yet. Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton. The aim of our study is to determine the frequency of IBS in AS, and to reveal its relationship with other factors, primarily with disease activity. Materials and Methods: 145 patients with AS in the rheumatology clinic of Namık Kemal University were included. Along with demographic, clinical and laboratory data of the patients, disease activity and biologic drug use were recorded. The diagnosis and type of IBS were examined according to ROME III criteria. Results: Prevalence of IBS in patients with AS was 31.7%. Frequency of IBS was significantly higher in higher disease activity group (BASDAI>4) and in patients treated with biological agents (p values <0.001, 0.010, respectively). IBS was significantly higher in female patients by gender and young patients (<50) by age (p: 0.012 and p: 0.01 respectively). Conclusion: IBS, when compared to the normal population, was found to be higher (%31,7) in patients with AS. The relationship between AS disease activity score and IBS suggests the effect of inflammation in pathogenesis. As a result, in patients with AS, especially with high disease activity, gastroenterological complaints should be questioned; and IBS as frequent comorbidity, shouldn’t be ignored in the follow-up

Özet

ÖzAmaç: İrritabl barsak sendromu (İBS), barsak alışkanlıklarında değişim ve kronik karın ağrısı ile karakterize bağırsağın fonksiyonel birhastalığıdır. İBS’ nin Romatoid artrit (RA) gibi inflamatuar patolojilerle artmış birlikteliğine rağmen, patofizyolojisinde inflamasyonun rolünetleştirilebilmiş değildir. Ankilozan Spondilit (AS) başlıca aksiyel iskelet sistemini tutan, kronik inflamatuvar bir hastalıkdır. Çalışmamızınamacı AS’ de İBS sıklığını tespit etmek ve bunun başta hastalık aktivitesi olmak üzere diğer faktörlerle ilişkisini ortaya koymaktır.Materyal ve Metot: Çalışmaya Namık Kemal Üniversitesi romatoloji kliniğindeki 145 AS tanılı hasta dahil edildi. Hastaların demografik,klinik ve laboratuvar verileri ile birlikte hastalık aktivitesi ve biyolojik ilaç kullanımı kaydedildi. ROMA III kriterlerine göre İBS tanısı ve tipiincelendi.Bulgular: AS hastalarındaki İBS sıklığı %31.7 idi. İBS sıklığı hastalık aktivitesi yüksek olan (BASDAI>4) ve biyolojik ajan tedavisialanlarda anlamlı şekilde yüksekti (p<0.001 ve p: 0.01 sırasıyla). Cinsiyetler arasında İBS kadın hastalarda, yaşa göre ise gençhastalarda (<50 yaş) anlamlı şekilde yüksekti (p: 0.012 ve p<0.01 sırasıyla).Sonuç: İBS; AS hastalarında normal popülasyona kıyasla daha yüksek (%31.7) tespit edildi. AS hastalık aktivite skoru ile İBS arasındakiilişki patogenezde inflamasyonun etkisini düşündürdü. Sonuç olarak özellikle hastalık aktivitesi yükse

🔖

Cite This Article

AVCI, O., METE, R., SOLMAZ, D. (2020). The Prevelance of Irritable Bowel Syndrome in Patients with Ankylosing Spondylitis. Namık Kemal Tıp Dergisi, Cilt: 8 - Sayı: 2, 117–123. https://ajindex.com/articles/340892

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643-50
  2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21 e4
  3. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000
  4. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-58
  5. Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. Can J Gastroenterol. 2005;19(4):231-4
  6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91
  7. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107(12):1793-801; quiz 802
  8. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986;27(1):37-40
  9. Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology. 1994;106(4):945-50
  10. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122(7):1778-83
  11. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(2):404- 10
  12. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123(6):1972-9
  13. Garcia Carrasco M, Mendoza Pinto C, Lopez Colombo A, Mendez Martinez S, Andari Sawaya R, Munoz Guarneros M, et al. Irritable bowel syndrome-type symptoms in female patients with mild systemic lupus erythematosus: frequency, related factors and quality of life. Neurogastroenterol Motil. 2013;25(12):958-66
  14. Myasoedova E, Talley NJ, Manek NJ, Crowson CS. Prevalence and risk factor